{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T20:07:18Z","timestamp":1747166838179,"version":"3.40.5"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"vor","delay-in-days":52,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.lrr.2024.100452","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T08:34:48Z","timestamp":1708677288000},"page":"100452","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Long-term follow-up of efficacy and safety in elderly patients with chronic myeloid leukemia treated with intermittent low dose dasatinib therapy"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5287-2770","authenticated-orcid":false,"given":"Masahiro","family":"Imamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reiki","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Sugita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2024.100452_bib0001","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/ejh.13081","article-title":"Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia","volume":"101","author":"Ota","year":"2018","journal-title":"Eur. J. Haematol"},{"key":"10.1016\/j.lrr.2024.100452_bib0002","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.clml.2017.02.023","article-title":"Elderly patients with chronic myeloid leukemia benefit from a dasatinib dose as low as 20mg","volume":"17","author":"Itamura","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.lrr.2024.100452_bib0003","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2169\/internalmedicine.9035-17","article-title":"The efficacy of reduced-dose dasatinib as a subsequent therapy in patients with chronic myeloid leukemia in the chronic phase: the LD-CML study of the Kanto CML study group","volume":"57","author":"Iriyama","year":"2018","journal-title":"Intern. Med."},{"key":"10.1016\/j.lrr.2024.100452_bib0004","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/ajh.26689","article-title":"Low-dose dasatinib 50mg\/day versus standard-dose dasatinib 100mg\/day as frontline therapy in chronic mueloid leukemia in chronic phase: a prospective score analysis","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.lrr.2024.100452_bib0005","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.clml.2023.05.009","article-title":"Low-dose dasatinib (50mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results","volume":"23","author":"Gener-Ricos","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.lrr.2024.100452_bib0006","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.clml.2022.11.006","article-title":"Attenuated dose dasatinib in newly diagnosed chronic myeloid leukemia chronic phase patients in India","volume":"23","author":"Ahmed","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.lrr.2024.100452_bib0007","first-page":"155","article-title":"Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy","volume":"4","author":"Serpa","year":"2020","journal-title":"Clin. Med. Insights: Oncol"},{"key":"10.1016\/j.lrr.2024.100452_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3727\/096504015X14452563485986","article-title":"What is the optimal dose and schedule for dasatinib in chronic myeloid leukemia: two case reports and review of the literature","volume":"23","author":"Jamieson","year":"2016","journal-title":"Oncol. Res."},{"key":"10.1016\/j.lrr.2024.100452_bib0009","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/bjh.17286","article-title":"TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia","volume":"193","author":"Claudiani","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.lrr.2024.100452_bib0010","doi-asserted-by":"crossref","first-page":"e902","DOI":"10.1016\/S2352-3026(21)00333-1","article-title":"Low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase (DAVLEC): a single-arm, multicentre phase 2 trial","volume":"8","author":"Murai","year":"2021","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.lrr.2024.100452_bib0011","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/ggi.12604","article-title":"Efficacy of intermittently administered dasatinib with a reduced dose in an elderly patient with chronic myeloid leukemia","volume":"16","author":"Imamura","year":"2016","journal-title":"Geriatr. Gerontol. Int"},{"key":"10.1016\/j.lrr.2024.100452_bib0012","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/ggi.13238","article-title":"Plasma and intracellular concentrations in an elderly patient with leukemia receiving low-dose dasatinib therapy","volume":"18","author":"Imamura","year":"2018","journal-title":"Geriatr. Gerontol. Int."},{"key":"10.1016\/j.lrr.2024.100452_bib0013","first-page":"85","article-title":"Differential effects of dosing regimen on the safety and efficacy of a phase III study","volume":"5","author":"Wang","year":"2013","journal-title":"Clin. Pharmacol."},{"key":"10.1016\/j.lrr.2024.100452_bib0014","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/ggi.14713","article-title":"Analysis of drug transporter gene polymorphisms in an elderly patient with chronic myeloid leukemia successfully treated with intermittent low dose dasatinib","volume":"23","author":"Nakamura","year":"2023","journal-title":"Geriatr. Gerontol. Int."},{"key":"10.1016\/j.lrr.2024.100452_bib0015","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.1182\/blood-2013-01-480194","article-title":"Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia","volume":"121","author":"Russo","year":"2013","journal-title":"Blood"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048924000426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048924000426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T17:11:39Z","timestamp":1718903499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048924000426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":15,"alternative-id":["S2213048924000426"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2024.100452","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term follow-up of efficacy and safety in elderly patients with chronic myeloid leukemia treated with intermittent low dose dasatinib therapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2024.100452","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100452"}}